The following is excerpted from the question-and-answer section of the transcript.
(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)
Question: Brandon Richard Folkes - Cantor Fitzgerald & Co., Research Division - Analyst
: Congratulations on all the progress this year and in the quarter. I'm going to ask on Zepzelca. Can you talk about your expectations for the ATLANTIS
trial? And what are your range of threshold for a successful outcome here? I know in the past, you've talked about this trial serving as a confirmatory
trial even if it's not stacked. So can you just elaborate a little bit more around that scenario? And then if ATLANTIS is not confirmatory, how soon
should we expect you to begin entering confirmatory trial of the monotherapy?
REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us
consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.
AUGUST 04, 2020 / 8:30PM, JAZZ.OQ - Q2 2020 Jazz Pharmaceuticals PLC Earnings Call
Question: Gary Jay Nachman - BMO Capital Markets Equity Research - Analyst
: On Xywav, and congrats on that approval, how do you expect payers will handle the 2 products with pricing at parity? Have you been preparing
payers for this transition from Xyrem? And what prelaunch activities are you planning on doing on the low-sodium benefits to help facilitate uptake
and to try and get to the majority of that switch by 2023 that Dan talked about?
Question: Gary Jay Nachman - BMO Capital Markets Equity Research - Analyst
: Okay. And other prelaunch activities, I don't know if you could comment, on that in terms of low-sodium benefit?
REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us
consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.
AUGUST 04, 2020 / 8:30PM, JAZZ.OQ - Q2 2020 Jazz Pharmaceuticals PLC Earnings Call
Question: Gregory B. Gilbert - Truist Securities, Inc., Research Division - Analyst
: It's Truist at this point. Looks like WAKIX is off to a decent start, Bruce, according to an S-1. I was curious if you or your teammates had any updated
thoughts on where or how that product is being used. And do you see the potential addition of cataplexy to its label should that occur as a
meaningful change to the competitive profile?
Question: Gregory B. Gilbert - Truist Securities, Inc., Research Division - Analyst
: And Bruce, no hard feelings about the name. You have a lot of new names to keep up with.
| 
